Novo Nordisk stock news
On July 3, 2026, market analysis indicated that Novo Nordisk (NVO) shares may be approximately 16% overvalued following the implementation of the U.S. Medicare "GLP--1 Bridge" program. While the program has driven a short--term share price increase of nearly 20% over the last 30 days by expanding patient access to Wegovy, analysts suggest the current valuation may exceed the company's intrinsic fair value based on discounted cash flow models. This assessment reflects growing market scrutiny over whether recent gains fully account for intensifying competition and long--term growth sustainability in the obesity treatment sector.